AngioDynamics, Inc. (ANGO): Price and Financial Metrics

AngioDynamics, Inc. (ANGO): $5.39

0.02 (+0.37%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

ANGO Price/Volume Stats

Current price $5.39 52-week high $12.62
Prev. close $5.37 52-week low $5.26
Day low $5.27 Volume 532,700
Day high $5.54 Avg. volume 532,217
50-day MA $5.89 Dividend yield N/A
200-day MA $7.51 Market Cap 214.82M

ANGO Stock Price Chart Interactive Chart >

ANGO POWR Grades

  • Value is the dimension where ANGO ranks best; there it ranks ahead of 87.41% of US stocks.
  • ANGO's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • ANGO ranks lowest in Momentum; there it ranks in the 24th percentile.

ANGO Stock Summary

  • The ratio of debt to operating expenses for ANGIODYNAMICS INC is higher than it is for about just 0.22% of US stocks.
  • With a year-over-year growth in debt of -100%, ANGIODYNAMICS INC's debt growth rate surpasses merely 0% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ANGO comes in at 15.75% -- higher than that of 89.4% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ANGIODYNAMICS INC, a group of peers worth examining would be CSPI, GGG, PLAB, ALOT, and ITT.
  • Visit ANGO's SEC page to see the company's official filings. To visit the company's web site, go to www.angiodynamics.com.

ANGO Valuation Summary

  • ANGO's EV/EBIT ratio is -72.4; this is 595.89% lower than that of the median Healthcare stock.
  • ANGO's EV/EBIT ratio has moved down 112 over the prior 238 months.

Below are key valuation metrics over time for ANGO.

Stock Date P/S P/B P/E EV/EBIT
ANGO 2023-12-29 0.9 0.7 48.5 -72.4
ANGO 2023-12-28 0.9 0.7 49.4 -74.2
ANGO 2023-12-27 1.0 0.7 49.7 -74.7
ANGO 2023-12-26 0.9 0.7 49.3 -73.9
ANGO 2023-12-22 0.9 0.7 49.2 -73.8
ANGO 2023-12-21 0.9 0.7 48.0 -71.7

ANGO Growth Metrics

    The 3 year revenue growth rate now stands at -12.93%.
  • The 4 year net income to common stockholders growth rate now stands at 295.21%.
  • Its year over year cash and equivalents growth rate is now at -56.14%.
Over the past 70 months, ANGO's revenue has gone down $28,364,000.

The table below shows ANGO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 327.934 -17.477 -32.714
2022-09-30 320.785 -23.035 -32.579
2022-06-30 316.219 -7.194 -26.547
2022-03-31 306.063 -3.555 -39.749
2021-12-31 303.275 11.107 -38.335
2021-09-30 297.765 20.614 -34.252

ANGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANGO has a Quality Grade of D, ranking ahead of 15.86% of graded US stocks.
  • ANGO's asset turnover comes in at 0.521 -- ranking 88th of 186 Medical Equipment stocks.
  • CLPT, EW, and IVC are the stocks whose asset turnover ratios are most correlated with ANGO.

The table below shows ANGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-08-31 0.521 0.541 -0.324
2021-05-31 0.503 0.539 -0.282
2021-02-28 0.464 0.531 -1.297
2020-11-30 0.434 0.540 -1.344
2020-08-31 0.407 0.551 -1.516
2020-05-31 0.385 0.569 -1.758

ANGO Price Target

For more insight on analysts targets of ANGO, see our ANGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.00 Average Broker Recommendation 1.5 (Moderate Buy)

AngioDynamics, Inc. (ANGO) Company Bio


AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.


ANGO Latest News Stream


Event/Time News Detail
Loading, please wait...

ANGO Latest Social Stream


Loading social stream, please wait...

View Full ANGO Social Stream

Latest ANGO News From Around the Web

Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

LATHAM, N.Y., December 21, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan 42nd Annual Healthcare Conference at 9:00

Yahoo | December 21, 2023

Why AngioDynamics (ANGO) Outpaced the Stock Market Today

The latest trading day saw AngioDynamics (ANGO) settling at $7.63, representing a +1.87% change from its previous close.

Yahoo | December 19, 2023

AngioDynamics (ANGO) Stock Drops Despite Market Gains: Important Facts to Note

AngioDynamics (ANGO) closed at $6.91 in the latest trading session, marking a -0.72% move from the prior day.

Yahoo | December 11, 2023

AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024

LATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2024 before the market open on Friday, January 5, 2024. The Company’s management will host a conference call at 8:00 a.m. ET the same

Yahoo | December 7, 2023

AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism

LATHAM, N.Y., December 07, 2023--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a clinical study aimed at evaluating the safety and efficacy of the Company’s Alp

Yahoo | December 7, 2023

Read More 'ANGO' Stories Here

ANGO Price Returns

1-mo -12.92%
3-mo -28.42%
6-mo -24.19%
1-year -56.00%
3-year -74.72%
5-year -75.84%
YTD -31.25%
2023 -43.06%
2022 -50.07%
2021 79.91%
2020 -4.25%
2019 -20.47%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!